M.PHARMACY – I YEAR I SEMESTER (PCI)				
		Course		
S.No	Course	code and	Course outcome	
		number		
		C <sub>(MPH101T)</sub> 1	To <b>recall and relate</b> the instrumental methods of analysis such as electrochemical, spectroscopic, chromatographic and electrophoretic techniques with volumetric methods of analysis. ( <b>UNDERSTAND</b> , <b>ANALYSE</b> )	
		С <sub>(МРН101Т)</sub> 2	To <u>demonstrate</u> the interaction of <u>EMR</u> with matter and its phenomenon in various spectroscopic techniques; affinity of matter with stationary and mobile phase; temperature induced physical & chemical changes in matter; potential differences in sample solutions and to study various factors affecting the analysis. ( <u>REMEMBER</u> , <u>UNDERSTAND, EVALUATE</u> )	
01	Modern Pharmaceutical Analytical Techniques Theory (MPH101T)	C <sub>(MPH101T)</sub> 3	To <u>identify and categorise</u> organic and inorganic compounds with different functional groups and to understand their structure at atomic, ionic, group and molecular level to recommend an appropriate spectroscopic technique for analysis. ( <u>UNDERSTAND</u> , <u>EVALUATE, APPLY</u> )	
		C <sub>(MPH101T)</sub> 4	To <u>demonstrate</u> the theory, principle, construction and working of instrument components and the methodology employed for the analysis of drugs in various samples. ( <u>UNDERSTAND</u> )	
		C <sub>(MPH101T)</sub> 5	To <b>gain</b> knowledge on X-ray crystallographic techniques, immunological assays and thermal methods of analysis.	
		С <sub>(МРН101Т)</sub> 6	To <b><u>summarize</u></b> the applications of various analytical techniques in relation to characterization of polymers, designing formulation and evaluation of formulation. ( <b><u>REMEMBER</u></b> , <b><u>APPLY</u></b> , <b><u>ANALYSE</u></b> )	
		C <sub>(MPH102T)</sub> 1	To <u>describe</u> about the basic concepts of Sustained release and Controlled release formulations.( <b>REMEMBER</b> )	
		C <sub>(MPH102T)</sub> 2	To <u>discuss</u> about the Dosage forms for personalized Medicine and categories of patients for personalized medicines.( <b>REMEMBER</b> )	
02	Drug Delivery System Theory (MPH102T)	С <sub>(МРН102Т)</sub> З	To <u>explain</u> about the Rate controlled drug delivery systems and feedback regulated drug delivery systems.( <u>UNDERSTAND</u> )	
		С <sub>(МРН102Т)</sub> 4	To <u>explain</u> about the methods of formulation and its evaluations of Gastro-Retentive Drug Delivery Systems and Buccal Drug Delivery Systems.( <u>UNDERSTAND</u> )	
		C <sub>(MPH102T)</sub> 5	To describe the barriers of drug permeation in	

			Occular Drug Delivery Systems, formulation
			and Evaluation of Transdermal Drug Delivery
			Systems ( <b>REMEMBER</b> )
		Садиностьб	To <b>explain</b> about the Formulation and
		C(MPH1021)0	Evaluation of delivery systems of proteins and
			vaccines Delivery Systems (UNDERSTAND)
		CARTILICATE 1	To <b>describe</b> about the basic concepts of
		C(MPH1031)1	preformulation studies( <u><b>REMEMBER</b></u> )
		C <sub>(MPH103T)</sub> 2	To <u>discuss</u> about the dispersion systems,
			parenterals and optimization
			process( <u>UNDERSTAND</u> )
		C <sub>(MPH103T)</sub> 3	To <u>explain</u> about the validation of process,
			equipment and product ( <u>UNDERSTAND</u> )
03		C <sub>(MPH103T)</sub> 4	To <u>describe</u> the c <u>GMP</u> concepts of layout of
00	Modern Pharmaceutics Theory		building, services and their maintenance
	(MPH103T)		&about the production management
			( <u>UNDERSTAND</u> )
		C <sub>(MPH103T)</sub> 5	To <u>describe</u> the concepts of compression and
			compaction ( <b><u>REMEMBER</u></b> )
		C <sub>(MPH103T)</sub> 6	To <b><u>explain</u></b> about the parameters of
			consolidation and their applications
			( <u>UNDERSTAND</u> )
		C <sub>(MPH104T)</sub> 1	To <u>explain</u> the Documentation in
	Regulatory Affair Theory (MPH104T)		Pharmaceutical industry and Generic drugs
			product development ( <u>UNDERSTAND</u> )
		C <sub>(MPH104T)</sub> 2	To <u>develop</u> knowledge on Regulatory
			requirements for product approval( <u>CREATE</u> )
		C <sub>(MPH104T)</sub> 3	Interpret the post approval regulatory affairs
			and ICH-Guidelines of ICH- Q, S, E, M
			( <u>UNDERSTAND</u> )
04		C <sub>(MPH104T)</sub> 4	To <b><u>discuss</u></b> the Regulatory requirements of EU,
••			MHRA, TGA and ROW countries
			( <u>UNDERSTAND</u> )
		C <sub>(MPH104T)</sub> 5	To <u>develop</u> knowledge on Non clinical drug
			development and Investigation of medicinal
			products dossier ( <u>CREATE</u> )
		$C_{(MPH104T)}6$	To <u>explain</u> the developing clinical trial
			protocols and institutional review board,
			pharmacovigilance safety monitoring in clinical
			triais(UNDERSTAND)
		$C_{(MPH105PA)}$	To <b><u>evaluate</u></b> the drug(s) by various analytical
05	Pharmaceutics Practical I MPH105PA		techniques (EVALUATE)
		C <sub>(MPH105PA</sub> 2	To <b>demonstrate</b> the working of Gas
			Chromatography(UNDERSTAND)
		C <sub>(MPH105PA)</sub> 3	To <u>demonstrate</u> of HPLC ( <u>UNDERSTAND</u> )
		C <sub>(MPH105PA)</sub> 4	To <b>determine</b> pre-formulation studies of the
			F

			given drug( <u>APPLY</u> )
		С <sub>(МРН105РА)</sub> 5	To <u>analyze</u> the effect of binder on disintegration of tablet( <u>ANALYZE</u> )
		С <sub>(МРН105РА)</sub> б	To <u>determine</u> the flow properties of given drug ( <u>APPLY</u> )
		C <sub>(MPH105PB)</sub> 1	To <u>discuss</u> the effect of various factors on drug dissolution ( <u>UNDERSTAND</u> )
		С(МРН105РВ2	To <u>demonstrate</u> the powder characteristics by constructing heckle plots( <u>UNDERSTAND</u> )
06	Pharmaceutical Practical II MPH105PB	С(мрн105рв)3	To <u>characterize</u> the comparative dissolution studies between various dosage forms ( <u>ANALYZE</u> )
		C <sub>(MPH105PB)</sub> 4	To <u>evaluate</u> the different dosage forms( <u>EVALUATE</u> )
		C <sub>(MPH105PB)</sub> 5	To <b>design</b> and <b>evaluate</b> different oral dosage forms( <b>CREATE</b> )
		С(МРН105РВ)6	To <u>design</u> and <u>evaluate</u> of different trasdermaldosage forms( <u>CREATE</u> )
07	Seminar/Assignment	C <sub>(SEMINAR)</sub> 1	To recall the technical knowledge gained in the design and development of various formulations ( <b>REMEMBER</b> )
		C <sub>(SEMINAR)</sub> 2	To <b>compare</b> and <b>differentiate</b> various pharmaceutical techniques involved in the nanotechnology and targeted drug delivery systems ( <b>ANALYZE</b> )
		C <sub>(SEMINAR)</sub> 3	To <u>develop</u> communication skills and build various models basing on the knowledge acquired in the molecular pharmaceutics ( <u>CREATE</u> )
		C <sub>(SEMINAR)</sub> 4	To <u>test</u> various hypothesis and develop problem solving skills in pilot development process ( <u>APPLY</u> )
		C <sub>(SEMINAR)</sub> 5	To <b><u>evaluate</u></b> the pharmacokinetic parameters and synthesize modelling techniques based on the information available ( <b>EVALUATE</b> )
		C <sub>(SEMINAR)</sub> 6	To <u>create</u> open minded environment in accepting the challenges and opportunities for designing the formulations ( <u>CREATE</u> )

M. <u>PHARMACY</u> – I <u>YEAR II SEMESTER</u> (PCI)				
S No	Course	Course code	Course outcome	
9.1NU	Course	and number		
		C 1	To <u>define</u> the concepts involved in targeting	
		C(MPH201T) 1	drug delivery specific to tumor and brain.	
			( <u>REMEMBER</u> )	
			To <b><u>review</u></b> the formulation, optimization and	
		C <sub>(MPH201T)</sub> 2	evaluation of microcapsules, nanoparticles,	
			liposomes and multiparticulate drug carrier	
			systems. (UNDERSTAND)	
			To <b><u>develop</u></b> nanoparticles, liposomes and	
01	MOLECULAR	C <sub>(MPH201T)</sub> 3	multiparticulate and other drug delivery	
UI	PHARMACEUTICS (NANO		systems for drug delivery. (CREATE)	
	TECH AND TARGETED		To <u>determine</u> the formulation of pulmonary	
	DDS)- THEORY MPH201T	C <sub>(MPH201T)</sub> 4	drug delivery systems and their evaluation.	
			( <u>APPLY</u> )	
		C <sub>(MPH201T)</sub> 5	To <b><u>discuss</u></b> the concepts of gene therapy and	
			liposomal gene delivery ( <b>UNDERSTAND</b> )	
			To <u>differentiate</u> the concepts of therapeutic	
		C (MPH201T) 6	antisense molecules, gene therapy and gene	
			expression systems. ( <u>ANALYZE</u> )	
		C <sub>(MPH202T)</sub> 1	To <u>recall</u> the basic concepts of absorption,	
			distribution, metabolism and excretion of drugs.	
			( <u>REMEMBER</u> )	
		C <sub>(MPH202T)</sub> 2	10 <u>understand</u> the mechanisms, interpret	
			various factors affecting drug absorption,	
			distribution, metabolism and excretion of drugs	
			(UNDERSTAND)	
	ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS- THEORY MPH202T	С(мрн202т) 3	nodels for the determination of pharmacokinetic	
			narameters (APPLV)	
02			To <b>analyze</b> the drug product performance by	
•-		C <sub>(MPH202T)</sub> 4	in-vitro, in-vivo and in-situ models	
			(ANALYZE)	
			To <b>determine</b> the bioavailability testing	
		С(мрн202т) 5	protocol of a drug and compare the	
		× /	bioequivalence among marketed products	
			( <u>APPLY</u> )	
			To <b>predict</b> pharmacokinetic and	
		C	pharmacodynamic drug interactions of modified	
		$C_{(MPH202T)} 0$	release drug products, targeted drug delivery	
			systems ( <u>EVALUATE</u> )	
			To <b><u>recall</u></b> the basics of computers in	
		C(MPH203T) 1	pharmaceutical research and development,	
03	COMPLITER AIDED DRUG		population modelling, and sensitivity analysis	
03	DELIVERY SYSTEM - THEORY MPH203T		( <u>REMEMBER</u> )	
		C <sub>(MPH203T)</sub> 2	To <u>illustrate</u> the quality by design principles,	
			computational modeling of drug disposition,	

			application of drug transporters (UNDERSTAND)
		С <sub>(МРН203Т)</sub> 3	To <u>determine</u> the concepts for computer-aided formulation development, ethics of computing in pharmaceutical research ( <u>APPLY</u> )
		C <sub>(MPH203T)</sub> 4	To <b>justify</b> the pharmacokinetic and pharmacodynamic characteristics of drugs by simulations ( <b>EVALUATE</b> )
		C <sub>(MPH203T)</sub> 5	To <u>assess</u> the applications of computers in clinical datamanagement (EVALUATE)
		C (MPH203T) 6	To <u>discuss</u> the impact of artificial intelligence, robotics and computational fluid dynamics ( <u>UNDERSTAND</u> )
		С(мрн204т) 1	To <u>remember</u> the principles of pre-formulation studies, drug-excipient incompatibility ( <u>REMEMBER</u> )
	Formulation Development of Pharmaceutical and Cosmetic Products -THEORY MPH204T	С <sub>(МРН204Т)</sub> 2	To <u>summarize</u> the important concepts of formulation additives, design of experiments and process development ( <u>UNDERSTAND</u> )
04		С(мрн204т) 3	To <b><u>apply</u></b> the principles of solubility, micellar solubilization, and invitro in vivo correlation ( <u>APPLY</u> )
		C <sub>(MPH204T)</sub> 4	To <u>develop</u> the product stability protocols and <u>ICH</u> guidelines for long term testing of the products ( <u>CREATE</u> )
		C <sub>(MPH204T)</sub> 5	To <b>justify</b> the formulation and evaluation of cosmetic products ( <b>EVALUATE</b> )
		С (МРН204Т) б	To <u>differentiate</u> the regulatory guidelines for herbal cosmetics, herbal ingredients used in hair care, skin care and oral care ( <u>ANALYZE</u> )
05	PHARMACEUTICS PRACTICAL III MPH205PA	С <sub>(МРН205РА)</sub> 1	To <u>recall</u> the basic principles of analytical techniques and their instrumentation used for drug formulation and characterization ( <b>DEMEMPER</b> )
		С <sub>(МРН205РА)</sub> 2	To <u>summarize</u> the preformulation studies and basic excipients used for various controlled/sustained drug delivery systems ( <u>UNDERSTAND</u> )
		С <sub>(МРН205РА)</sub> 3	To <b>infer</b> the use of various analytical instruments for estimation of drugs in various formulations ( <b>ANALYZE</b> )
		С(мрн205ра) 4	To <b>justify</b> the formulation techniques, prepare matrix tablets, floating tablets and cosmetics ( <b>EVALUATE</b> )
		C <sub>(MPH205PA)</sub> 5	To <u>assess</u> the drug release from sustained and controlled drug delivery systems ( <u>EVALUATE</u> )

		C (MPH205PA) 6	To <b><u>apply</u></b> the knowledge of dosage forms, construct kinetic plots and determine similarity factor ( <u>CREATE</u> )
	PHARMACEUTICS PRACTICAL IV MPH205PB	С(МРН205РВ) 1	To <b><u>recall</u></b> the basic techniques for using design of experiment software ( <u><b>REMEMBER</b></u> )
		C <sub>(MPH205PB)</sub> 2	To <u>compare</u> the data analysis techniques, and quality by design principles, sensitivity analysis, population modelling ( <u>ANALYZE</u> )
		С <sub>(МРН205РВ)</sub> 3	To <u>develop</u> various cosmetic products like creams, shampoos, toothpaste bases ( <u>CREATE</u> )
UO		С(мрн205рв) 4	To <u>test</u> for drug binding characteristics, cell permeation and bioavailability of the formulations ( <u>APPLY</u> )
		С(мрн205рв) 5	To <u>evaluate</u> the novel drug delivery systems (EVALUATE)
		C (MPH205PA) 6	To <b>design</b> formulations by QbD concept, use simulations for estimation of pharmacokinetics and pharmacodynamics ( <b>CREATE</b> )
07	SEMINAR/ ASSIGNMENT	C <sub>(SEMINAR)</sub> 1	To <u>recall</u> the technical knowledge gained in the design and development of various formulations ( <b>REMEMBER</b> )
		C <sub>(SEMINAR)</sub> 2	To <b>compare</b> and differentiate various pharmaceutical techniques involved in the nanotechnology and targeted drug delivery systems ( <b>ANALYZE</b> )
		C <sub>(SEMINAR)</sub> 3	To <b>develop</b> communication skills and build various models basing on the knowledge acquired in the molecular pharmaceutics ( <b>CREATE</b> )
		C <sub>(SEMINAR)</sub> 4	To <u>test</u> various hypothesis and develop problem solving skills in pilot development process ( <u>APPLY</u> )
		C <sub>(SEMINAR)</sub> 5	To <b><u>evaluate</u></b> the pharmacokinetic parameters and synthesize modelling techniques based on the information available ( <u><b>EVALUATE</b></u> )
		C (SEMINAR) 6	To <u>create</u> open minded environment in accepting the challenges and opportunities for designing the formulations ( <u>CREATE</u> )

M.PHARMACY – III SEMESTER (PCI)				
S No	Course	Course code	Course outcome	
3.110		and number		
			To <u>demonstrate</u> the general research	
		C	methodology including, study design and	
		$C_{(MRM301T)}$	strategies to eliminate errors/bias	
			(UNDERSTAND)	
			To <b><u>explain</u></b> the importance of biostatistics in	
		$C_{\alpha} = 2$	pharmacy: statistical tests of significance, non-	
		C(MRM3011)2	parametric tests, null hypothesis, P values and	
			degree of freedom ( <u>UNDERSTAND</u> )	
			To <u>discuss</u> the Medical Research regarding	
			values in medical ethics, conflicts between	
01		C(MRM3011)5	autonomy and beneficence and criticisms of	
<b>UI</b>	<b>Research Methodology &amp;</b>		orthodox medical ethics (UNDERSTAND)	
	<b>Biostatistics (MRM301T)</b>		To <u>describe</u> the ethics committees, online	
		$C_{(MRM301T)}4$	business practise, conflicts of interest and	
			vendor relationships ( <u>UNDERSTAND</u> )	
		С(мрм301т).5	To <u>explain</u> the <u>CPCSEA</u> guidelines for	
		- (WIRW5011)-	laboratory animal facility ( <u>UNDERSTAND</u> )	
			To <u>explain</u> about the Declaration of Helsinki	
		С(мрм301т)6	regarding basic principles for all medical	
			research and medical research combined with	
			medical care (UNDERSTAND)	
		C.1	To <u>select</u> the scientific concept based on	
	Journal club		literature and define the objectives of research	
			(ANALYZE)	
		C.2	To <u>summarize</u> the hypothesis and summarize	
		<u> </u>	the concept for presentation (UNDERSTAND)	
		C.3	10 discuss in a meeting, discuss SWOI	
03			analysis, the design and methods used in	
02		C 4	To endure the variables and their inter	
		C.4	rolationships (ANALVZE)	
		C 5	To conclude the results and to discuss its	
		C.5	significance (FVALUATE)	
		<u> </u>	To annraise the concept for societal needs	
		C.0	acknowledge and improve presentation skills	
			(FVALUATE)	
			To <b>recall</b> the technical knowledge gained in the	
		C 1	design and development of various	
		0.1	formulations ( <b>REMEMBER</b> )	
			To <b>compare</b> and <b>differentiate</b> various	
03	Discussion / Presentation		pharmaceutical techniques involved in the	
	(Proposal Presentation)	C.2	nanotechnology and targeted drug delivery	
			systems (ANALYZE)	
		C.3	To <b>develop</b> communication skills and build	
			various models basing on the knowledge	

			acquired in the molecular pharmaceutics
		C 4	(CREATE) To test various hypothesis and develop problem
		0.1	solving skills in pilot development process
			( <u>APPLY</u> )
		C.5	To evaluate the pharmacokinetic parameters and
			synthesize modelling techniques based on the information available ( <b>EVALUATE</b> )
		C.6	To <u>create</u> open minded environment in
			accepting the challenges and opportunities for
			designing the formulations ( <u>CREATE</u> )
	Research Work	<b>C</b> 1	To <u>recall</u> the fundamentals, carry out literature
		C.1	review on proposed research topic and identify
			research problem ( <u><b>REMEMBER</b></u> )
		C.2	To <u>summarize</u> the requirements as per the proposed research (UNDERSTAND)
		C.3	To <b>construct</b> the research hypothesis
04			( <u>CREATE</u> )
		C.4	To design research experiments meticulously
			and documentation as per format (CREATE)
		C.5	To <b><u>evaluate</u></b> and <u><b>conclude</b></u> the results using
			statistical analysis (EVALUATE)
		C.6	To <b>appraise</b> societal application and
			appreciation (EVALUATE)

M.PHARMACY -			- IV SEMESTER (PCI)
S No Course		Course code	Course outcome
5.110	Course	and number	
		C 1	To <u>select</u> the scientific concept based on literature and
			define the objectives of research ( <u>ANALYZE</u> )
		C.2	To <u>summarize</u> the hypothesis and summarize the
		0.2	concept for presentation ( <u>UNDERSTAND</u> )
		C.3	To <u>discuss</u> in a meeting, discuss <u>SWOT</u> analysis, the
		~ .	design and methods used in concept (UNDERSTAND)
01	Journal club	C.4	To <u>analyze</u> the variables and their inter relationships
			(ANALYZE)
		C.5	To <u>conclude</u> the results and to discuss its significance
			( <u>EVALUATE</u> )
		C.6	To <u>appraise</u> the concept for societal needs,
			acknowledge and improve presentation skills
			(EVALUATE)
		C 1	on proposed research topic and identify research
	Research Work	C.1	problem ( <b>REMEMBER</b> )
			To summarize the requirements as per the proposed
		C.2	research (UNDERSTAND)
		C.3	To <b>construct</b> the research hypothesis ( <b>CREATE</b> )
02		C.4	To <b>design</b> research experiments meticulously and
		0.1	documentation as per format ( <b>CREATE</b> )
		C.5	To <b>evaluate</b> and conclude the results using statistical
			analysis (EVALUATE)
		C.6	To <b>appraise</b> societal application and appreciation
			( <u>EVALUATE</u> )
			To <b><u>recall</u></b> the technical knowledge gained in the design
		C.1	and development of various formulations
			( <u>REMEMBER</u> )
	Discussion / Final Presentation		To <b><u>compare</u></b> and <u><b>differentiate</b></u> various pharmaceutical
		C.2	techniques involved in the nanotechnology and targeted
			drug delivery systems ( <u>ANALYZE</u> )
		C.3	To <u>develop</u> communication skills and build various
03			models basing on the knowledge acquired in the
05		C 4	To <b>test</b> various hypothesis and develop problem
		0.4	solving skills in pilot development process ( <b>APPLY</b> )
		C.5	To <b>evaluate</b> the pharmacokinetic parameters and synthesize
			modeling techniques based on the information available
			( <u>EVALUATE</u> )
		C.6	To create open minded environment in accepting the
			challenges and opportunities for designing the
			formulations ( <u>CREATE</u> )